Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

ClosureFAST vs. Laser Ablation for the Treatment of GSV Disease: A Multicenter, Single-Blinded, Randomized Study. (RECOVERY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00509392
Recruitment Status : Completed
First Posted : July 31, 2007
Results First Posted : July 12, 2017
Last Update Posted : July 12, 2017
Sponsor:
Collaborator:
VNUS Medical Technologies, A Covidien Company
Information provided by (Responsible Party):
Medtronic Endovascular

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The objective of this post-market study is to compare the post-procedure recovery between two types of minimally invasive catheter treatments for venous disease in the Great Saphenous Vein.

Condition or disease Intervention/treatment Phase
Venous Reflux Device: Seg. RF Ablation & ClosureFAST catheter Device: Endovenous Laser Phase 4

Detailed Description:
Comparison of the post-procedure recovery of radiofrequency (RFA) treatment vs. laser treatment.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 69 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Radiofrequency Endovenous ClosureFAST vs. Laser Ablation for the Treatment of Great Saphenous Reflux: A Multicenter, Single-Blinded, Randomized Study (RECOVERY)
Study Start Date : March 2007
Actual Primary Completion Date : January 2008
Actual Study Completion Date : January 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: GERD

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Seg. RF Ablation & ClosureFAST catheter
Seg. RF Ablation & ClosureFAST catheter
 Device: Seg. RF Ablation & ClosureFAST catheter
Seg. RF Ablation & ClosureFAST catheter
Other Name: VNUS
Active Comparator: Endovenous Laser
Treatment invention of venous disease with an Endovenous Laser.
 Device: Endovenous Laser
laser catheter
Other Name: Commercially approved laser catheter systems.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Pain [ Time Frame: 48 Hour ]
    Pain 0-10 scale (10 most severe)

  2. Pain [ Time Frame: 1 Week ]
    Pain 0-10 scale (10 most severe)

  3. Pain [ Time Frame: 2 Weeks ]
    Pain 0-10 scale (10 most severe)

  4. Pain [ Time Frame: 1 Month ]
    Pain 0-10 scale (10 most severe)

  5. Tenderness [ Time Frame: 48 Hour ]
    Tenderness 0-10 scale (10 most severe)

  6. Tenderness [ Time Frame: 1 Week ]
    Tenderness 0-10 scale (10 most severe)

  7. Tenderness [ Time Frame: 2 Weeks ]
    Tenderness 0-10 scale (10 most severe)

  8. Tenderness [ Time Frame: 1 Month ]
    Tenderness 0-10 scale (10 most severe)

  9. Ecchymosis [ Time Frame: 48 Hours post treatment (no baseline) ]

    0-5 scale (5 most severe) 0: None

    1. <25%
    2. 25-50%
    3. 50-75%
    4. 75-100%
    5. Above or below treated (tx) segment

  10. Ecchymosis [ Time Frame: 1 Week post treatment (no baseline) ]

    0-5 scale (5 most severe) 0: None

    1. <25%
    2. 25-50%
    3. 50-75%
    4. 75-100%
    5. Above or below tx segment

  11. Ecchymosis [ Time Frame: 2 Weeks post treatment (no baseline) ]

    0-5 scale (5 most severe) 0: None

    1. <25%
    2. 25-50%
    3. 50-75%
    4. 75-100%
    5. Above or below tx segment

  12. Ecchymosis [ Time Frame: 1 Month post treatment (no baseline) ]

    0-5 scale (5 most severe) 0: None

    1. <25%
    2. 25-50%
    3. 50-75%
    4. 75-100%
    5. Above or below tx segment

  13. Complications [ Time Frame: 1 month ]
    Sequelae at any follow-up


Secondary Outcome Measures :
  1. VCSS [ Time Frame: 48 Hours ]

    Venous Clinical Severity Score (0-30 total overall score):

    0(minimum)- No evidence of venous disease 30(maximum)- Severe venous disease


  2. VCSS [ Time Frame: 1 Week ]

    Venous Clinical Severity Score (0-30 total overall score):

    0(minimum)- No evidence of venous disease 30(maximum)- Severe venous disease


  3. VCSS [ Time Frame: 2 Weeks ]

    Venous Clinical Severity Score (0-30 total overall score):

    0(minimum)- No evidence of venous disease 30(maximum)- Severe venous disease


  4. VCSS [ Time Frame: 1 Month ]

    Venous Clinical Severity Score (0-30 total overall score):

    0(minimum)- No evidence of venous disease 30(maximum)- Severe venous disease


  5. Change in CIVIQ QOL [ Time Frame: 48 Hours ]

    Chronic Venous Insufficiency Questionnaire(CIVIQ) for Quality of Life(QOL). (Min 20- Max 100).

    Global index and an outline of 4 quality-of-life dimensions: "pain" (4 items), "physical" (4 items), "psychological" (9 items), and "social" (3 items). A low global (total) score corresponds to greater patient comfort.

    Change from Baseline


  6. Change in CIVIQ QOL [ Time Frame: 1 Week ]

    Chronic Venous Insufficiency Questionnaire(CIVIQ) for Quality of Life(QOL). (Min 20- Max 100).

    Global index and an outline of 4 quality-of-life dimensions: "pain" (4 items), "physical" (4 items), "psychological" (9 items), and "social" (3 items). A low global (total) score corresponds to greater patient comfort.

    Change from Baseline


  7. Change in CIVIQ QOL [ Time Frame: 2 Week ]

    Chronic Venous Insufficiency Questionnaire(CIVIQ) for Quality of Life(QOL) (Min 20- Max 100).

    Global index and an outline of 4 quality-of-life dimensions: "pain" (4 items), "physical" (4 items), "psychological" (9 items), and "social" (3 items). A low global (total) score corresponds to greater patient comfort.

    Change from Baseline


  8. Change in CIVIQ QOL [ Time Frame: 1 Month ]

    Chronic Venous Insufficiency Questionnaire(CIVIQ) for Quality of Life(QOL). (Min 20- Max 100).

    Global index and an outline of 4 quality-of-life dimensions: "pain" (4 items), "physical" (4 items), "psychological" (9 items), and "social" (3 items). A low global (total) score corresponds to greater patient comfort.

    Change from Baseline



Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All subjects must provide written informed consent.
  • Must be a candidate for either treatment with Radiofrequency Ablation (RFA) or endovenous laser.

Exclusion Criteria:

  • Subjects who require additional treatments in either leg within 30 days before or after the study procedure.
  • Subjects who are participating in another investigational study.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00509392


Locations
Layout table for location information
United States, Oregon
Oregon Health Sciences
Portland, Oregon, United States, 97239
Sponsors and Collaborators
Medtronic Endovascular
VNUS Medical Technologies, A Covidien Company
Investigators
Layout table for investigator information
Study Director: Lian Cunningham, MD VNUS Medical Technologies, A Covidien Company
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications of Results:

Layout table for additonal information
Responsible Party: Medtronic Endovascular
ClinicalTrials.gov Identifier: NCT00509392    
Other Study ID Numbers: CVL-06-03
First Posted: July 31, 2007    Key Record Dates
Results First Posted: July 12, 2017
Last Update Posted: July 12, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Keywords provided by Medtronic Endovascular:
Varicose veins, venous reflux, GSV disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
 Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases